Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T3DO
|
|||
| Former ID |
DIB003449
|
|||
| Drug Name |
IRX-5183
|
|||
| Synonyms |
AGN-195183; NRX-195183; NRX-5183; VTP-195183; VTP-5183; IRX-5183 (oral, autoimmune disease), Io Therapeutics; RARa (oral, cancer/autoimmune disease), Io Therapeutics; RARa agonist (topical, skin/eye diseases), Io Therapeutics; Retinoic acid receptor alpha agonist (oral, cancer/autoimmune disease), Io Therapeutics; Retinoic acid receptor alpha agonist (topical, skin/eye diseases), Io Therapeutics; IRX-5183 (oral, cancer/autoimmune disease), Io Therapeutics; IRX-5183 (topical, skin/eye diseases), Io Therapeutics
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Vitae Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H22ClF2NO4
|
|||
| Canonical SMILES |
CC1(CCC(C2=C1C=C(C(=C2Cl)O)C(=O)NC3=CC(=C(C(=C3)F)C(=O)O)F)(C)C)C
|
|||
| InChI |
1S/C22H22ClF2NO4/c1-21(2)5-6-22(3,4)16-12(21)9-11(18(27)17(16)23)19(28)26-10-7-13(24)15(20(29)30)14(25)8-10/h7-9,27H,5-6H2,1-4H3,(H,26,28)(H,29,30)
|
|||
| InChIKey |
PNAWUIKCVQSLFG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 367273-07-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Retinoic acid receptor alpha (RARA) | Target Info | Agonist | [2], [3] |
| Retinoic acid receptor RXR (RXR) | Target Info | Agonist | [1] | |
| KEGG Pathway | Pathways in cancer | |||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| Pathway Interaction Database | Retinoic acid receptors-mediated signaling | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Vitamin A and Carotenoid Metabolism | |||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Adipogenesis | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. J Mol Med (Berl). 2004 Feb;82(2):116-25. | |||
| REF 3 | Tamibarotene. Drugs Today (Barc). 2007 Aug;43(8):563-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.